NASDAQ:INDP

Indaptus Therapeutics - INDP Stock Forecast, Price & News

$2.10

-0.09 (-4.11%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.08
▼
$2.27
50-Day Range: $2.10
▼
$3.33
52-Week Range: $1.89
▼
$8.17

Volume: 43,261 shs
Average Volume: 14,933 shs
Market Capitalization: $17.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.50

Indaptus Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 638.1% Upside
$15.50 Price Target
Short Interest: Healthy
0.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$29,255 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.85) to ($2.74) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

144th out of 1,075 stocks

Pharmaceutical Preparations Industry

50th out of 537 stocks

3.5

Analyst's Opinion

Consensus Rating
Indaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.50, Indaptus Therapeutics has a forecasted upside of 638.1% from its current price of $2.10.
Amount of Analyst Coverage
Indaptus Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.45% of the float of Indaptus Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Indaptus Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Indaptus Therapeutics has recently decreased by 8.06%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Indaptus Therapeutics does not currently pay a dividend.
Dividend Growth
Indaptus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INDP.

0.0

News and Social Media Coverage

Search Interest
Only 1 people have searched for INDP on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Indaptus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,255.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
36.00% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 19.25% of the stock of Indaptus Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Indaptus Therapeutics are expected to decrease in the coming year, from ($1.85) to ($2.74) per share.
Price to Book Value per Share Ratio
Indaptus Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Indaptus Therapeutics

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INDP Stock News Headlines

September 6, 2022 | apnews.com

Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

September 6, 2022 | finance.yahoo.com

Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

August 17, 2022 | reuters.com

Indaptus Therapeutics Inc

August 8, 2022 | finance.yahoo.com

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

June 9, 2022 | finance.yahoo.com

Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

June 3, 2022 | finance.yahoo.com

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

May 23, 2022 | finance.yahoo.com

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

May 19, 2022 | msn.com

Indaptus Shares Jump On FDA Nod For Early-Stage Solid Tumor Trial

May 19, 2022 | investorplace.com

Why Is Indaptus Therapeutics (INDP) Stock Up 20% Today?

May 19, 2022 | seekingalpha.com

Indaptus stock soars 37% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors

May 19, 2022 | finance.yahoo.com

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

May 18, 2022 | finance.yahoo.com

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 14, 2022 | seekingalpha.com

Indaptus Therapeutics GAAP EPS of -$0.41

May 12, 2022 | finance.yahoo.com

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 3, 2022 | finance.yahoo.com

Indaptus Therapeutics, Inc. (NASDAQ:INDP) insiders placed bullish bets worth US$2.4m in the last 12 months

April 20, 2022 | finance.yahoo.com

Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit

March 23, 2022 | finance.yahoo.com

Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference

March 21, 2022 | benzinga.com

Recap: Indaptus Therapeutics Q4 Earnings

March 17, 2022 | finance.yahoo.com

Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit

February 3, 2022 | au.finance.yahoo.com

Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I (INDP)

January 31, 2022 | benzinga.com

HC Wainwright & Co. Assumes Indaptus Therapeutics at Buy, Announces Price Target of $15

January 5, 2022 | finance.yahoo.com

Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

January 3, 2022 | finance.yahoo.com

Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer

December 1, 2021 | finance.yahoo.com

Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors

November 15, 2021 | finance.yahoo.com

Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INDP Company Calendar

Last Earnings: 8/08/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INDP
CUSIP: N/A
CIK: 1857044
Web: intecpharma.com
Phone: (646) 374-8050
Fax: 972-2586-9176
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.50
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +638.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,710,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -40.03%
Return on Assets: -35.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.18
Quick Ratio: 9.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.38 per share
Price / Book: 0.48

Miscellaneous

Outstanding Shares: 8,260,000
Free Float: 5,286,000
Market Cap: $17.35 million
Optionable: Not Optionable
Beta: 0.92

Key Executives

Mr. Jeffrey A. Meckler (Age 55)
CEO & Director
Comp: $958.84k

Dr. Michael J. Newman Ph.D. (Age 66)
Founder, Chief Scientific Officer & Director
Comp: $468.82k

Mr. Walt Addison Linscott Esq. (Age 61)
Chief Bus. Officer
Comp: $719.13k

Mr. Nir Sassi (Age 46)
CFO, Sec. & Treasurer

Dr. Boyan Vesselinov Litchev M.D. (Age 55)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INDP Stock - Frequently Asked Questions

Should I buy or sell Indaptus Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INDP shares.
View INDP analyst ratings or view top-rated stocks.
What is Indaptus Therapeutics' stock price forecast for 2022?: 2 equities research analysts have issued 1 year target prices for Indaptus Therapeutics' stock. Their INDP share price forecasts range from $15.00 to $16.00. On average, they expect the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 638.1% from the stock's current price.
View analysts price targets for INDP or view top-rated stocks among Wall Street analysts.
How have INDP shares performed in 2022?: Indaptus Therapeutics' stock was trading at $5.70 on January 1st, 2022. Since then, INDP stock has decreased by 63.2% and is now trading at $2.10.
View the best growth stocks for 2022 here.
When is Indaptus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our INDP earnings forecast.

How were Indaptus Therapeutics' earnings last quarter?: Indaptus Therapeutics, Inc. (NASDAQ:INDP) issued its earnings results on Monday, August, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.03.
What is Indaptus Therapeutics' stock symbol?: Indaptus Therapeutics trades on the NASDAQ under the ticker symbol "INDP."
How do I buy shares of Indaptus Therapeutics?: Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Indaptus Therapeutics' stock price today?: One share of INDP stock can currently be purchased for approximately $2.10.
How much money does Indaptus Therapeutics make?: Indaptus Therapeutics (NASDAQ:INDP) has a market capitalization of $17.35 million.
How can I contact Indaptus Therapeutics?: Indaptus Therapeutics' mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The official website for the company is intecpharma.com. The company can be reached via phone at (646) 374-8050, via email at will.oconnor@sternir.com, or via fax at 972-2586-9176.

This page (NASDAQ:INDP) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Indaptus Therapeutics - INDP Stock Forecast, Price & News

Indaptus Therapeutics MarketRank™ Forecast

Overall MarketRank™